NCI-NCI-24-001: DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Office of National Drug Control Policy notices from 2024.
Office of National Drug Control Policy offered grants of up to $2.5 million to nonprofits. It expected to make one award worth $2.5 million in total. Applications closed on September 16, 2024.
From the official notice on Grants.gov, last changed August 12, 2024. Checked November 7, 2026.
- Award ceiling$2.5 million
- Total funding$2.5 million
- Expected awards1
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | August 12, 2024 |
|---|---|
| Deadline | September 16, 2024 |
| Archived by Grants.gov | October 16, 2024 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Is this a realistic fit?
- Past DFC NATIONAL COMMUNITY ANTIDRUG COALITION INSTITUTE awards averaged $2.5 million; this notice allows up to $2.5 million per award.
- Most of the program's money (100% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
Adolescence is a critical risk period for substance use initiation and adverse outcomes related to substance use, particularly as drug use has been found to escalate between ages 12 and 19. The goal of substance use prevention efforts is to prevent and/or delay the first use of substances. Research shows that early age of onset is an important predictor for the development of a substance use disorder later in life. Further, research shows that prevention interventions can have positive long-term effects in reducing substance use. Recognizing that preventing or delaying initiation of substance use can confer important health and social benefits, the purpose of the NCI is to serve as the training and technical assistance partner for DFC and non-DFC funded community coalitions across the country by enhancing the capacity of the prevention workforce and others in the prevention community to implement evidence-based interventions.
Who has won DFC NATIONAL COMMUNITY ANTIDRUG COALITION INSTITUTE grants before
From fiscal 2021 to 2025, DFC NATIONAL COMMUNITY ANTIDRUG COALITION INSTITUTE (95.003) awarded $10.0 million across 4 grant awards, an average of $2.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Cadca | Virginia | 4 | $10.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is NCI-NCI-24-001 still open?
No. It closed on September 16, 2024.
Who can apply for DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)?
Office of National Drug Control Policy accepted applications from nonprofits.
What is the deadline for DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)?
Closed September 16, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.5 million each. About $2.5 million in total for one award.
Who has won DFC NATIONAL COMMUNITY ANTIDRUG COALITION INSTITUTE grants before?
The largest recipients over five fiscal years were Cadca. The program made 4 awards worth $10.0 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)